ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022)
ARS Pharmaceuticals (SPRY) reported Long-Term Investments of $24.2 million for Q2 2022, down 44.93% sequentially from $44.0 million in Q1 2022.
ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 2 years of Long-Term Investments data on file, last reported at $24.2 million in Q2 2022.
- For the quarter ending Q2 2022, Long-Term Investments changed N/A year-over-year to $24.2 million; the trailing twelve-month figure through Jun 2022 stood at $24.2 million (changed N/A YoY), and the FY2021 full-year result was $64.8 million, changed N/A from the prior year.
- Long-Term Investments slipped to $24.2 million in Q2 2022, from $44.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $64.8 million in Q4 2021 to a low of $24.2 million in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 505,194.89 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 24.22 Mn |
| Mar 31, 2022 | 43.97 Mn |
| Dec 31, 2021 | 64.78 Mn |
| Sep 30, 2021 | 39.94 Mn |